- Home
- LPCN vs RCG Comparison
LPCN vs RCG Comparison
Compare LPCN & RCG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPCN
- RCG
- Stock Information
- Founded
- LPCN 1997
- RCG 1994
- Country
- LPCN United States
- RCG United States
- Employees
- LPCN N/A
- RCG N/A
- Industry
- LPCN Biotechnology: Pharmaceutical Preparations
- RCG Investment Managers
- Sector
- LPCN Health Care
- RCG Finance
- Exchange
- LPCN Nasdaq
- RCG Nasdaq
- Market Cap
- LPCN 16.1M
- RCG 18.2M
- IPO Year
- LPCN N/A
- RCG N/A
- Fundamental
- Price
- LPCN $3.00
- RCG $2.64
- Analyst Decision
- LPCN Strong Buy
- RCG
- Analyst Count
- LPCN 2
- RCG 0
- Target Price
- LPCN $9.00
- RCG N/A
- AVG Volume (30 Days)
- LPCN 29.3K
- RCG 5.9K
- Earning Date
- LPCN 08-07-2025
- RCG 01-01-0001
- Dividend Yield
- LPCN N/A
- RCG 0.98%
- EPS Growth
- LPCN N/A
- RCG N/A
- EPS
- LPCN N/A
- RCG N/A
- Revenue
- LPCN $3,674,834.00
- RCG N/A
- Revenue This Year
- LPCN N/A
- RCG N/A
- Revenue Next Year
- LPCN N/A
- RCG N/A
- P/E Ratio
- LPCN N/A
- RCG N/A
- Revenue Growth
- LPCN N/A
- RCG N/A
- 52 Week Low
- LPCN $2.68
- RCG $1.52
- 52 Week High
- LPCN $7.61
- RCG $1.90
- Technical
- Relative Strength Index (RSI)
- LPCN 40.07
- RCG 53.31
- Support Level
- LPCN $3.10
- RCG $2.60
- Resistance Level
- LPCN $3.39
- RCG $2.71
- Average True Range (ATR)
- LPCN 0.18
- RCG 0.06
- MACD
- LPCN -0.00
- RCG 0.00
- Stochastic Oscillator
- LPCN 0.00
- RCG 70.31
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
About RCG RENN Fund Inc
RENN Fund Inc is active in the financial services domain. It is a a registered, non-diversified, closed-end management investment company formed to provide return through capital appreciation and income by a long-term, value-oriented investment process that invests in a wide variety of financial instruments, including but not limited to, common stocks, fixed-income securities including convertible and non-convertible debt securities or loans, distressed debt, warrants, and preferred stock, exchange-traded funds and exchange-traded notes, and other instruments. It invests in various industries, including communication services, surgical and medical instruments and apparatus, oil and gas, medical chemicals, botanical products, etc.